Results 161 to 170 of about 7,260 (206)

Combined Therapy of Pilocarpine or Latanoprost with Timolol Versus Latanoprost Monotherapy

Survey of Ophthalmology, 2002
Adjunctive intraocular pressure (IOP)-lowering therapy is widely used today, as one-third of all patients being treated for glaucoma need additional therapy to reach and maintain healthy IOPs. Timolol, latanoprost, and pilocarpine are three potent drugs that have been used in combination to reduce IOP.
Michael Diestelhorst, Jean Philippe Nordmann, Carol B. Toris   +2 more
openaire   +3 more sources

Synthesis of latanoprost diastereoisomers

Chirality, 2005
A new synthesis of latanoprost diastereoisomers is described which utilizes a highly stereoselective Michael addition of higher-order cuprate to a chiral cyclopentenone derived from G-lactone in the crucial skeleton-forming step.
Josef Hajicek, Iva Obadalova, Tomas Pilarcik, Marketa Slavikova   +3 more
openaire   +3 more sources

Latanoprost Loaded in Polymeric Nanocapsules for Effective Topical Treatment of Alopecia

AAPS PharmSciTech, 2020
Latanoprost has recently been used to treat alopecia as it causes an increase in the capillary density of patients. This work presents for the first time the development of polymeric nanocapsules containing latanoprost for the topical treatment of ...
Ana Christina S Oliveira, Paula M. Oliveira, Marcilio Cunha-Filho, Taís Gratieri, G. M. Gelfuso   +4 more
semanticscholar   +1 more source

Latanoprost, a balanced prostaglandin

Expert Review of Ophthalmology, 2019
Introduction: Glaucoma is a leading cause of blindness and represents a significant global health and economic concern. Prostaglandin analogs such as latanoprost – which act to reduce intraocular pressure by enhancing uveoscleral flow and slow the development and progression of glaucoma – are recommended as a first-line monotherapy.Areas covered: We ...
Jose M. Martinez-de-la-Casa, Joanna Wierzbowska, Shaantanu Donde   +2 more
openaire   +2 more sources

An Evaluation of the Rate of Nonresponders to Latanoprost Therapy

Journal of Glaucoma, 2006
To determine the proportion of patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who do not respond to latanoprost therapy.Three hundred forty consecutive patients with a new diagnosis of POAG or OH, or previously treated only with a beta-blocker and after an appropriate washout period, were treated with latanoprost for 1 ...
Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G, Carassa R, Mastropasqua L, Quaranta L, MARCHINI, Giorgio, Ratiglia R, Orzalesi N.   +11 more
openaire   +5 more sources

Effect of Latanoprost on Choroidal Thickness

Journal of Glaucoma, 2018
Purpose:The purpose of this study was to evaluate the changes in choroidal thickness during the use of latanoprost eyedrops which shift fluid to the suprachoroidal space and change choroidal perfusion.Materials and Methods:This prospective study included 34 eyes of 17 bilateral glaucoma or ocular hypertensive patients who had no previous hypotensive ...
Nedime Sahinoglu-Keskek, Handan Canan
openaire   +3 more sources

Latanoprost in hypotensive therapy of glaucoma

Vestnik oftal'mologii, 2018
The review presents an analysis of therapeutic effectiveness, safety and pharmacokinetics of latanoprost - the reference representative of the prostaglandin group, summarizes the experience of its clinical use in glaucoma as monotherapy and in combination with antihypertensive drugs of other pharmacological groups, its possible effect on the ...
V P Erichev, V S Zinina
openaire   +3 more sources

Anterior uveitis associated with latanoprost

American Journal of Ophthalmology, 1998
To report the association of anterior uveitis with the use of latanoprost.We studied four patients with complicated open-angle glaucoma who had anterior uveitis associated with the use of latanoprost. The uveitis was unilateral and occurred only in the eye receiving latanoprost in three patients.
Albert S Khouri, John Bullock, Andrew J. Michael, Tony Realini, Prasad S. Kulkarni, Robert M. Feldman, Ronald E. Warwar, Robert D. Fechtner, Thom J. Zimmerman   +8 more
openaire   +3 more sources

A Comparative Ocular Pharmacokinetics Study of Preservative-Free Latanoprost Unit-Dose Eye Drops and a Benzalkonium Chloride-Preserved Branded Product Following Topical Application to Rabbits.

Journal of Ocular Pharmacology and Therapeutics, 2020
Purpose: To evaluate the aqueous humor pharmacokinetics of a preservative-free 0.005% latanoprost unit-dose eye drop (test drug) compared with that of a benzalkonium chloride (BAK)-preserved 0.005% latanoprost branded product (control drug) following ...
Tianyang Zhou, Yan Miao, Zhengyan Li, P. Lu, Zhen Liang, Jingjing Yang, Jijun He, Huiyun Xia, Zhen Zhang, Junjie Zhang   +9 more
semanticscholar   +1 more source

Lash Ptosis Caused by Latanoprost

American Journal of Ophthalmology, 2005
To report a case of lash ptosis caused by latanoprost.Observational case report.Retrospective chart review.A 61-year-old, ocular hypertensive man who was using latanoprost OU presented with trichomegaly and bilateral lash ptosis. The lash ptosis had not resolved 6 months after stopping latanoprost, and anterior lamellar repositions were performed.
Casson, R., Selva-Nayagam, D.
openaire   +4 more sources